Beijing Kawin Technology Share-Holding Past Earnings Performance
Past criteria checks 5/6
Beijing Kawin Technology Share-Holding has been growing earnings at an average annual rate of 12.5%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 12.3% per year. Beijing Kawin Technology Share-Holding's return on equity is 7.7%, and it has net margins of 8.2%.
Key information
12.5%
Earnings growth rate
4.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 12.3% |
| Return on equity | 7.7% |
| Net Margin | 8.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Beijing Kawin Technology Share-Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,432 | 118 | 907 | 134 |
| 31 Dec 23 | 1,412 | 117 | 899 | 134 |
| 30 Sep 23 | 1,326 | 105 | 890 | 113 |
| 30 Jun 23 | 1,236 | 85 | 867 | 106 |
| 31 Mar 23 | 1,181 | 80 | 855 | 116 |
| 31 Dec 22 | 1,160 | 83 | 852 | 114 |
| 30 Sep 22 | 1,275 | 98 | 954 | 96 |
| 30 Jun 22 | 1,184 | 109 | 889 | 90 |
| 31 Mar 22 | 1,144 | 111 | 846 | 88 |
| 31 Dec 21 | 1,144 | 107 | 849 | 77 |
| 30 Sep 21 | 1,033 | 98 | 741 | 70 |
| 30 Jun 21 | 1,002 | 85 | 716 | 67 |
| 31 Mar 21 | 912 | 80 | 639 | 60 |
| 31 Dec 20 | 862 | 76 | 603 | 56 |
| 30 Sep 20 | 825 | 55 | 607 | 51 |
| 31 Dec 19 | 825 | 54 | 618 | 35 |
| 31 Dec 18 | 706 | 45 | 508 | 53 |
| 31 Dec 17 | 491 | 27 | 354 | 43 |
| 31 Dec 15 | 268 | 24 | 163 | 0 |
| 31 Dec 14 | 225 | 12 | 131 | 0 |
| 31 Dec 13 | 200 | 17 | 102 | 0 |
Quality Earnings: 688687 has high quality earnings.
Growing Profit Margin: 688687's current net profit margins (8.2%) are higher than last year (6.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688687's earnings have grown by 12.5% per year over the past 5 years.
Accelerating Growth: 688687's earnings growth over the past year (47.6%) exceeds its 5-year average (12.5% per year).
Earnings vs Industry: 688687 earnings growth over the past year (47.6%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: 688687's Return on Equity (7.7%) is considered low.